Cancer News and Research

Latest Cancer News and Research

Mammograms may increase risk for ‘over-diagnosis’ of cancers: Study

According to a new study from Norway up to a fourth of breast cancers found through mammograms are harmless and would not cause noticeable disease during the women's lifetimes. Such women are said to be over-diagnosed, because their cancers would not have caused symptoms or death. Over-diagnosis is a problem because women may receive tests and treatment they did not actually need.

2 Apr 2012

Melanoma on the rise especially amongst the young

Women under 40 are hit hardest by the escalating incidence of melanoma, according to a Mayo Clinic study published in the April issue of Mayo Clinic Proceedings, out today. Researchers examined records from a decades-long database of all patient care in Olmsted County, Minn., and looked for first-time diagnoses of melanoma in patients 18-39 from 1970 to 2009. Melanoma cases increased eightfold among women in that time and fourfold for men, the authors say. However, death rates from melanoma fell during the same period, suggesting that early interventions may be helping to save some lives, said the researchers.

2 Apr 2012

Regular walking regimen can benefit cancer survivors

Researchers have affirmed that pancreatic cancer patients can literally take a step-by-step approach to combat fatigue. A study published in the April issue of the Journal of the American College of Surgeons reports that patients who underwent an operation as part of their cancer treatment and then started a regular walking regimen experienced less fatigue than cancer survivors who did not do the walking program.

2 Apr 2012

Study identifies specific chemical in smokeless tobacco products that induces oral cancer

The chemical (S)-N'-nitrosonornicotine, or (S)-NNN, which is present in smokeless tobacco products, is a strong oral carcinogen, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

2 Apr 2012

CYP1B1 protein may be a potential target for intervention in head and neck cancer

Squamous cell carcinoma of the head and neck-which typically arises from thin, flat cells that line moist surfaces inside the mouth, nose and throat-is the sixth most common type of cancer worldwide, and it has a relatively low five-year survival rate and a high recurrence rate.

2 Apr 2012

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

Special fatty molecules pave novel way to treat infections, autoimmune diseases, allergies and cancer

An international research team led by scientists from Singapore Immunology Network (SIgN) under the Agency of Science, Technology and Research (A*STAR) discovered that a special class of fatty molecules is essential for activating a unique group of early-responding immune cells.

2 Apr 2012

Safe method for destroying cancer cells using death cap mushroom poison

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin.

2 Apr 2012

Targeting inflammatory pathways may lead to new therapies

Scientists at Fox Chase Cancer Center have uncovered more details about how defects in components of the machinery that makes new proteins can lead to blood and other cancers.

2 Apr 2012

TYRX enrolls 1000th patient in CITADEL/CENTURION AIGISRx Antibacterial Envelope studies

TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with cardiovascular implantable electronic devices (CIEDs), announced today that the 1000th patient has been enrolled into the CITADEL & CENTURION clinical studies evaluating the company's AIGISRx Antibacterial Envelope.

2 Apr 2012

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar Therapeutics announced today that the first subjects were dosed last week in a Phase 1 clinical study to evaluate the pharmacokinetics and safety of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate.

2 Apr 2012

RainDance introduces new panel for cancer mutation screening

RainDance Technologies, Inc., the Digital Biology company, today announced the worldwide availability of its new panel for cancer mutation screening research using any next-generation sequencing (NGS) system.

2 Apr 2012

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Oncolytics Biotech Inc. announced today that it has completed enrollment in the first, 80 patient stage of its Phase III clinical trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018).

2 Apr 2012

Life Technologies expands TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the expansion to its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools designed to detect an additional 241 of the most common mutations in 21 cancer genes.

2 Apr 2012

Inovio awarded U.S. DOD grant to advance non-invasive surface electroporation delivery device

Inovio Pharmaceuticals, Inc. announced today it has received a U.S. Department of Defense Small Business Innovation Research Grant to advance the development of a low-cost, non-invasive surface electroporation (EP) delivery device and test its utility in combination with Inovio's novel synthetic DNA vaccines against viruses with bioterrorism potential, including hanta, puumala, arenavirus and pandemic influenza.

2 Apr 2012

$Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint$

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Aeterna Zentaris Inc. today announced that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.

2 Apr 2012

Blocking PRC2 protein may help protect against AML

Scientists at Cold Spring Harbor Laboratory have identified a candidate drug target for treating acute myeloid leukemia, a white blood cell cancer that proliferates out of control in the bone marrow.

2 Apr 2012

Clinical data for cabozantinib to be presented at ASCO annual meeting

Exelixis, Inc. announced today that its lead compound, cabozantinib, will be the subject of nine separate data presentations at the upcoming Annual Meeting of the American Society of Clinical Oncology.

2 Apr 2012

Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, and Life Technologies Corporation today announced Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays.

2 Apr 2012

ProteinSimple introduces Sally Western Blot

ProteinSimple today introduced Sally as the next member of the revolutionary Simple Western product family. Sally eliminates a critical bottleneck in large-scale protein research and biopharmaceutical development – manual Western Blot analysis. With Sally, researchers can perform 96 Simple Westerns in a single automated experiment.

From ProteinSimple 2 Apr 2012

Cancer News and Research

Latest Cancer News and Research

Mammograms may increase risk for ‘over-diagnosis’ of cancers: Study

Melanoma on the rise especially amongst the young

Regular walking regimen can benefit cancer survivors

Study identifies specific chemical in smokeless tobacco products that induces oral cancer

CYP1B1 protein may be a potential target for intervention in head and neck cancer

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

Special fatty molecules pave novel way to treat infections, autoimmune diseases, allergies and cancer

Safe method for destroying cancer cells using death cap mushroom poison

Targeting inflammatory pathways may lead to new therapies

TYRX enrolls 1000th patient in CITADEL/CENTURION AIGISRx Antibacterial Envelope studies

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

RainDance introduces new panel for cancer mutation screening

Enrollment complete in Oncolytics REOLYSIN combination trial for head and neck cancers

Life Technologies expands TaqMan Mutation Detection Assays

Inovio awarded U.S. DOD grant to advance non-invasive surface electroporation delivery device

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Blocking PRC2 protein may help protect against AML

Clinical data for cabozantinib to be presented at ASCO annual meeting

Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays

ProteinSimple introduces Sally Western Blot

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in